Walleye Capital
CRBP icon

Walleye Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Walleye Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-55,236
Closed -$652K – 4376
2024
Q4 		$652K Buy
55,236
+18,273
+49% +$306K ﹤0.01% 2757
2024
Q3 		$763K Sell
36,963
-113,428
-75% -$5.8M ﹤0.01% 2916
2024
Q2 		$6.81M Buy
150,391
+17,807
+13% +$749K 0.01% 1044
2024
Q1 		$5.2M Buy
+132,584
New +$3.27M 0.01% 1261
2021
Q3 		– Sell
-5,627
Closed -$309 – 1630
2021
Q2 		$309 Buy
+5,627
New +$312K 0.01% 912

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Walleye Capital's CRBP Position: Q1 2025 in Review

Walleye Capital sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 55,236 shares — an estimated $652K sold.

Walleye Capital first reported a position in CRBP in Q2 2021 and held it in 5 quarters. The position peaked at $6.81M in Q2 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Walleye Capital reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 55,236 Corbus Pharmaceuticals shares in Q1 2025, an estimated $652K.
  • Walleye Capital first reported a position in Corbus Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Walleye Capital's Corbus Pharmaceuticals position peaked at $6.81M in Q2 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.